Plasma urokinase receptor levels in patients with colorectal cancer: relationship to prognosis - PubMed (original) (raw)
. 1999 May 19;91(10):869-74.
doi: 10.1093/jnci/91.10.869.
Affiliations
- PMID: 10340907
- DOI: 10.1093/jnci/91.10.869
Plasma urokinase receptor levels in patients with colorectal cancer: relationship to prognosis
R W Stephens et al. J Natl Cancer Inst. 1999.
Abstract
Background: The proteolytic enzyme plasmin, which is generated from the precursor plasminogen by the action of urokinase plasminogen activator, is thought to play a role in tumor cell invasion and metastasis. Urokinase plasminogen activator receptor (uPAR) is functionally involved in the cell surface activation (i.e., cleavage) of plasminogen. Increased tumor tissue levels of uPAR are associated with poor prognosis in several types of cancer. This retrospective study was undertaken to test the relationship between preoperative plasma levels of soluble uPAR (suPAR) and survival in patients with colorectal cancer.
Methods: suPAR levels in preoperative plasma from 591 patients with colorectal cancer were determined by use of a kinetic enzyme-linked immunosorbent assay and analyzed with respect to associations with postoperative survival, Dukes' stage, age, and serum carcinoembryonic antigen level. Plasma suPAR measurements were log transformed for survival analysis, which employed the Kaplan-Meier method and the Cox proportional hazards model. All P values reported are two-sided.
Results: Univariate analysis, using the log-transformed suPAR concentrations, demonstrated that there was an increasing risk of mortality with increasing plasma suPAR level (P<.0001). An arbitrary cut point, the median for all patients (1.37 ng/mL), divided patients with Dukes' stage B, C, or D disease into statistically different prognostic groups. In multivariate Cox analysis including Dukes' stage, age, and carcinoembryonic antigen level, the suPAR concentration independently predicted survival (P<.0001).
Conclusions: The preoperative plasma suPAR level independently predicted survival of patients with colorectal cancer. Further studies of plasma suPAR in patients with cancer are needed to evaluate the utility of plasma suPAR measurements and cut points in identifying high-risk patients among those with early stage disease.
Similar articles
- Preoperative plasma soluble urokinase plasminogen activator receptor as a prognostic marker in rectal cancer patients. An EORTC-Receptor and Biomarker Group collaboration.
Riisbro R, Christensen IJ, Nielsen HJ, Brünner N, Nilbert M, Fernebro E. Riisbro R, et al. Int J Biol Markers. 2005 Apr-Jun;20(2):93-102. Int J Biol Markers. 2005. PMID: 16011039 - Prognostic importance of the soluble plasminogen activator receptor, suPAR, in plasma from rectal cancer patients.
Fernebro E, Madsen RR, Fernö M, Brünner N, Bendahl P, Christensen IJ, Johnson A, Nilbert M. Fernebro E, et al. Eur J Cancer. 2001 Mar;37(4):486-91. doi: 10.1016/s0959-8049(00)00422-6. Eur J Cancer. 2001. PMID: 11267858 - Serum tetranectin is an independent prognostic marker in colorectal cancer and weakly correlated with plasma suPAR, plasma PAI-1 and serum CEA.
Høgdall CK, Christensen IJ, Stephens RW, Sørensen S, Nørgaard-Pedersen B, Nielsen HJ. Høgdall CK, et al. APMIS. 2002 Sep;110(9):630-8. doi: 10.1034/j.1600-0463.2002.1100906.x. APMIS. 2002. PMID: 12529016 - The urokinase plasminogen activator receptor in blood from healthy individuals and patients with cancer.
Brünner N, Nielsen HJ, Hamers M, Christensen IJ, Thorlacius-Ussing O, Stephens RW. Brünner N, et al. APMIS. 1999 Jan;107(1):160-7. doi: 10.1111/j.1699-0463.1999.tb01539.x. APMIS. 1999. PMID: 10190293 Review.
Cited by
- Targeted imaging of uPAR expression in vivo with cyclic AE105 variants.
Leth JM, Newcombe EA, Grønnemose AL, Jørgensen JT, Qvist K, Clausen AS, Knudsen LBS, Kjaer A, Kragelund BB, Jørgensen TJD, Ploug M. Leth JM, et al. Sci Rep. 2023 Oct 11;13(1):17248. doi: 10.1038/s41598-023-43934-w. Sci Rep. 2023. PMID: 37821532 Free PMC article. - Identification and validation of hub genes involved in foam cell formation and atherosclerosis development via bioinformatics.
Teng D, Chen H, Jia W, Ren Q, Ding X, Zhang L, Gong L, Wang H, Zhong L, Yang J. Teng D, et al. PeerJ. 2023 Oct 3;11:e16122. doi: 10.7717/peerj.16122. eCollection 2023. PeerJ. 2023. PMID: 37810795 Free PMC article. - SuPAR in major depression: Association with 26 weeks antidepressant response and 10-year depression outcomes.
Haupt TH, Elfving B, Eugen-Olsen J, Mors O, Köhler-Forsberg O. Haupt TH, et al. Brain Behav Immun Health. 2023 Sep 7;33:100685. doi: 10.1016/j.bbih.2023.100685. eCollection 2023 Nov. Brain Behav Immun Health. 2023. PMID: 37731957 Free PMC article. - ICAM-1-suPAR-CD11b Axis Is a Novel Therapeutic Target for Metastatic Triple-Negative Breast Cancer.
Li D, Hemati H, Park Y, Taftaf R, Zhang Y, Liu J, Cristofanilli M, Liu X. Li D, et al. Cancers (Basel). 2023 May 12;15(10):2734. doi: 10.3390/cancers15102734. Cancers (Basel). 2023. PMID: 37345070 Free PMC article. - Soluble Urokinase Plasminogen Activator Receptor Levels Correlation with Other Inflammatory Factors in Prognosis of Disability and Death in Patients with Ischemic Stroke.
Różański D, Szlufik S, Tomasiuk R, Milanowski Ł, Figura M, Saramak K, Myrcha P, Koziorowski D. Różański D, et al. Brain Sci. 2021 Dec 28;12(1):39. doi: 10.3390/brainsci12010039. Brain Sci. 2021. PMID: 35053782 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical